Industry
Biotechnology
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
February 02, 2024 | 1:04 pm
Portfolio Pulse from Benzinga Insights
January 31, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Insights
January 10, 2024 | 5:31 pm
Portfolio Pulse from Avi Kapoor
January 02, 2024 | 6:35 pm
Portfolio Pulse from Benzinga Insights
January 02, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Insights
January 01, 2024 | 5:30 pm
Portfolio Pulse from Benzinga Insights
December 29, 2023 | 5:31 pm
Portfolio Pulse from Avi Kapoor
December 28, 2023 | 6:07 pm
Portfolio Pulse from Benzinga Newsdesk
December 19, 2023 | 1:41 pm
Portfolio Pulse from Benzinga Insights
December 15, 2023 | 1:08 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.